HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

Table 1

Outcome of different GvHD prophylaxis regimens and different SC sources, in the context of a myeloablative conditioning regimen.

SC	Age	Phase of; disease		aGvHD; III-IV	cGvHD; mod-sev	NRM	REF
ATG based
BM + G-PB	25 y	CR + Ad	756	14%	53%	18%	[16]
G-PB	25 y	CR	99	17%	41%	30%	[25]
G-BM	37 y	CR + Ad	80	5%	17%	36%	[18]
PT-CY based
G-PB	46 y	CR	30	23%	27%	3%	[12]
G-PB	55 y	CR + Ad	40	7,5%	20%	17%	[14]
BM	47 y	CR + Ad	148	3%	16%	14%	[10]

CR + Ad: patients in complete remission and patients with advanced disease; SC: stem cell source; BM: bone marrow; G-PB: peripheral blood mobilized with GCSF; G-BM: BM mobilized with GCSF; aGvHD: acute GvHD, grades III-IV; cGvHD: chronic GvHD, moderate to severe; NRM: nonrelapse mortality; REF: reference number.
ATG: antithymocyte globulin; PT-CY: posttransplant cyclophosphamide.